FDA Sets Clock for ENSACOVE Patent Extension Review
Published Date: 3/6/2026
Notice
Summary
The FDA has officially set the review period for ENSACOVE, a human drug, so its patent holder can apply for extra patent time. This affects the drug company and anyone tracking patent extensions, with deadlines to challenge dates or diligence claims by May 5 and September 2, 2026. It’s a key step to keep innovation protected while making sure the process stays fair and on schedule.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
FDA Sets ENSACOVE Review Period
FDA determined ENSACOVE’s regulatory review period is 4,645 days total (4,288 days testing phase and 357 days approval phase). The determination uses an IND effective date of April 2, 2012, an NDA submission date of December 28, 2023, and an approval date of December 18, 2024; the applicant seeks 1,827 days of patent term extension.
Deadline to Seek Redetermination
Anyone who believes the published dates are incorrect may submit electronic or written comments and ask FDA for a redetermination by May 5, 2026. Electronic comments are accepted at https://www.regulations.gov until 11:59 p.m. Eastern Time on May 5, 2026; mailed paper comments must be received by that date to be timely.
Deadline to Petition on Due Diligence
Any interested person may petition FDA to determine whether the patent applicant acted with due diligence during the regulatory review period; petitions must be filed by September 2, 2026 and comply with 21 CFR 60.30 and related requirements. Petitions must be timely, follow submission rules in 21 CFR 10.20, contain sufficient facts, and certify service on the patent applicant.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2026-04490, Gulf Fishery Management Council; Public Meeting
The Gulf Fishery Management Council is hosting five in-person meetings from March 23 to April 17, 2026, to talk about important issues affecting Gulf fisheries, businesses, and communities. These meetings will help shape a plan to manage the Gulf’s fishery ecosystem better, but no new rules or costs will come from this. If you care about fishing and the Gulf environment, these meetings are where the future gets discussed!
Next: 2026-04492, Community Development Financial Institutions Fund; Announcement Type: Notice of Information Collection and Request for Public Comment
The Treasury Department wants your thoughts on their online Opportunity Zone Nomination Tool, which helps pick special low-income areas for investment. This is part of a plan to cut down on paperwork and make the process smoother for communities and agencies. If you want to share your ideas, send them by May 5, 2026—this could shape how money flows into neighborhoods that need it most!